Lipocalin-2 (LCN2) orchestrates AD pathogenesis through tripartite pathomechanisms: exacerbating neuroinflammatory cascades via microglial activation, dysregulating insulin/IGF-1 signaling axis in neuronal populations, and amplifying Aβ plaque-associated gliosis through astrocyte reactivity potentiation. Here, LCN2 is linked to Alzheimer disease.